<DOC>
	<DOCNO>NCT00254163</DOCNO>
	<brief_summary>The purpose research study find effect ( good bad ) combination Nipent+Cytoxan+Rituxan CLL cancer compare Fludara+Cytoxan+Rituxan . While drug approve Food Drug Administration ( FDA ) treatment cancer , combination experimental treatment CLL .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Rituximab Versus Pentostatin , Cyclophosphamide , Rituximab Previously Untreated Treated B-Cell Chronic Lymphocytic Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients eligible inclusion study meet follow criterion : Progressive , histologically proven Bcell CLL . Stage II , III , IV Bcell CLL , define Appendix III . Note : The pathology flow cytometry ( peripheral blood bone marrow ) report , do local laboratory document finding , must include source document . The SI must review pathology report flow cytometry report result ( include bone marrow aspirate analysis CD5 CD20 result ) fax , prior registration , confirm patient 's eligibility . Results consistent typical Bcell CLL . If Dr. Reynolds available review document , must review Dr. Nicholas J . Di Bella . Patient must CD20 + Patient must CD5+ ( CD5 &gt; 70 % ) No 1 prior course ( regimen ) chemotherapy , include Fludara Rituxan No prior radiation therapy , except treatment skin cancer nonmalignant condition . If patient lymph node involvement , CT scan confirm measurable tumor size ( lymph node must &gt; 1 cm long transverse diameter ) . SI notify IF patient replacement steroid time registration . Age great 18 year . ECOG performance status 02 ( Appendix I ) . Normal renal function ( creatinine &lt; 1.5 mg/dL BUN &lt; 25 mg/dL ) . Absolute neutrophil count ( ANC ) great 1,000 cells/µL , platelet count great 50,000 cells/µL , hemoglobin great 9 g/dL . Bilirubin le 2.0 mg/dL , AST ALT less 5 time upper limit normal . Negative serum pregnancy test within 7 day prior registration ( female patient childbearing potential ) . Agrees use acceptable method birth control , fertile patient ( male female ) , avoid pregnancy duration study least 3 month thereafter . A signed Patient Informed Consent Form obtain . A signed Patient Authorization Form obtain . EXCLUSION CRITERIA : Patients exclude study meet follow criterion : Any disease histologically confirm progressive , Stage II , III , IV CLL . Well differentiate lymphocytic lymphoma node without lymphocytosis . More 1 prior course ( regimen ) chemotherapy . Any radiation treatment CLL . Any prior Nipent . Known CD20 negative ( CD20 &lt; 20 % ) . Pregnant lactating , positive pregnancy test . Has history malignancy ( situ cervical cancer , carcinoma intraepithelial neoplasia , nonmelanoma skin cancer ) within last 5 year , could affect administration study drug assessment current CLL . Known HIV positive . Uncontrolled thyroid disease uncontrolled abnormal thyroid function . Note : Patients thyroid disease control medication may participate . A history recent , unstable organic heart disease stable organic heart disease LVEF &lt; 50 % . A known hypersensitivity Fludara , Nipent , Rituxan , Cytoxan , component drug . Autoimmune hemolytic anemia . Unable comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>